Entero Therapeutics Inc ENTO.OQ ENTO.O is expected to show change in quarterly revenue when it reports results on August 22 (estimated) for the period ending June 30 2024
LSEG's mean analyst estimate for Entero Therapeutics Inc is for a loss of $1.55 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Entero Therapeutics Inc is $36.00, above its last closing price of $0.30.
This summary was machine generated August 20 at 20:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)